Demographic Shift and Healthcare Demand - The world is experiencing a significant demographic shift with populations aging rapidly, where individuals aged 60 and older outnumber children under five for the first time in 2020, projected to exceed 2 billion by 2050 [2] - The U.S. population aged 65 and older is expected to nearly double by 2050, with those aged 85 and older projected to triple by 2060 [2] Geriatric Care Market Growth - The global geriatric care services market, valued at $1 trillion in 2022, is expected to more than double by 2033, driven by growth in pharmaceuticals, medical devices, long-term and home-based care, and digital health solutions [3] Healthcare Challenges in the U.S. - Mortality rates among seniors have increased by 4.5% annually, with a 50% rise for those aged 85 and older; Alzheimer's and dementia-related deaths are up 40% [4] - Hospital utilization is surging, with admissions rising by 25%, average stay lengthening, readmissions increasing by 20%, and emergency visits soaring by 40% [4] Pharmaceutical and Device Companies' Response - Pharmaceutical firms like Roche and Novo Nordisk are focusing on high-demand areas, while device makers such as Edwards Lifesciences and Stryker are advancing tools for chronic disease management [5] Digital Health Innovations - Digital health is transforming elder care with AI-powered diagnostics, remote monitoring, and wearables, leading to better outcomes and new revenue models [6] - The demand for home care is rising as more seniors choose to age at home, although a projected shortage of 2.3 million long-term care workers by 2030 poses challenges [6] Financial Trends in Senior Care - U.S. senior care spending exceeded $1 trillion in 2022 and could double by 2040, emphasizing the need for value-based models and efficient chronic disease management [7] Roche's Strategic Initiatives - Roche is advancing Alzheimer's diagnostics with the Elecsys Amyloid Plasma Panel, showing 91% sensitivity and 96.2% negative predictive value, and has announced a $50 billion investment in U.S. operations over five years [8][9] Novo Nordisk's Regulatory Wins - Novo Nordisk's Ozempic received FDA approval for reducing kidney disease progression and cardiovascular death in adults with Type 2 diabetes, and the company is investing €2.34 billion to upgrade its production facility in Italy [10][11] Edwards Lifesciences' Innovations - Edwards Lifesciences is focusing on aortic stenosis care, with new data showing early treatment reduces costs and improves outcomes; TAVR sales reached $1.05 billion in Q1 2025 [12][13] Stryker's Market Penetration - Stryker is making strategic investments in senior healthcare, enhancing capabilities in minimally invasive neurosurgery through acquisitions, and offering products designed to improve outcomes for elderly patients [14][15]

Group 1 - Trifork Switzerland has been selected as a subcontractor to Deloitte Switzerland for the DigiSanté framework agreement, focusing on healthcare standards [1][3] - The DigiSanté program aims to enhance the Swiss digital health infrastructure through standards-based development and secure data architecture [2][4] - The agreement allows for up to 144,000 hours of work over nine years, with a total value ranging from CHF 27.7 million to CHF 38.8 million [3] Group 2 - Deloitte and Trifork will leverage their combined expertise in standards and healthcare system architecture to support the Swiss Federal Office of Public Health [4][5] - Trifork has significant experience in regulated health software development and is involved in national initiatives like the electronic patient dossier [4][9] - The collaboration is seen as a strategic move to support the long-term goals of the Swiss Federal Office of Public Health [5]

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2025) - Victory Square Technologies Inc. (CSE: VST) (OTC Pink: VSQTF) ("Victory Square" or the "Company"), a venture builder that provides public investors with access to early-stage technology companies, today announced its financial results for the three months ended March 31, 2025, and shared an update on its key business focus areas for the remainder of the year.Q1 2025 Financial Highlights Adjusted Revenue: $6.528MGAAP Revenue: $4.540MCost of Good ...

SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O’Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company’s ...

Villers-lès-Nancy (France), July 03, 2025 – 06 :00pm (CET) Press Release Equasens announces the departure of Damien VALICON, as Deputy Chief Executive Officer and Director of the Pharmagest Division He will be replaced by François-Pierre MARQUIER as Director of the Pharmagest Division. *** Equasens Group (Euronext Paris™ - Compartment B - FR 0012882389 –$EQS), announces the departure of Damien VALICON, who held the position of Deputy Chief Executive Officer and Director of the Pharmagest Division for 18 mo ...

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:https://investor.resmed.com •Date:Thursday, ...

Villers-lès-Nancy, 1st July 2025 – 07:00 p.m. (CET) PRESS RELEASE RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING OF 25 JUNE 2025 Number of shares comprising the share capital: 15,174,125 Number of shares with voting rights: 14,830,415 Number of shares with voting rights possessed by shareholders presents or represented or having voted by mail: 13,173,125 That means a quorum of 88.83% of the 14,830,415 shares with voting rights: the Ordinary Annual General Me ...

Shares of Apollo Hospitals, India’s largest healthcare services firm, surged to a record Tuesday after it announced plans to merge its digital health and pharmacy businesses and spin them off as a new listed entity https://t.co/OsN2L4Xz4M ...

Villers-lès-Nancy (France), 30 June 2025 - 06:00 PM (CET) PRESS RELEASE EQUASENS ACQUIRES DIS AND RESURGENCES BUSINESSES, STRENGTHENING ITS POSITION IN THE MARKET OF SOFTWARE SOLUTIONS FOR HEALTHCARE ESTABLISHMENTS. Strengthening the position of a leading provider of software solutions for hospitals and the medical-social sector Growth strategy in action This acquisition is fully in line with Equasens' strategy for: developing software solutions for public health establishments, a market with numerous renew ...

Key Takeaways HIMS expects 2025 EPS growth of 170.4% vs. LFMD's 107.6%, signaling stronger profit momentum. HIMS is expanding into Europe via its ZAVA acquisition, targeting markets like Germany and France. LFMD's $299 Wegovy program has enrolled more than 75K patients, showing rapid traction and nationwide scale.Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space. This is bringing a new class of tech-driven innovators to the forefr ...